BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 28210005)

  • 21. Dissection of the transformation of primary human hematopoietic cells by the oncogene NUP98-HOXA9.
    Yassin ER; Sarma NJ; Abdul-Nabi AM; Dombrowski J; Han Y; Takeda A; Yaseen NR
    PLoS One; 2009 Aug; 4(8):e6719. PubMed ID: 19696924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.
    So CW; Karsunky H; Wong P; Weissman IL; Cleary ML
    Blood; 2004 Apr; 103(8):3192-9. PubMed ID: 15070702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PHD fingers of MLL block MLL fusion protein-mediated transformation.
    Muntean AG; Giannola D; Udager AM; Hess JL
    Blood; 2008 Dec; 112(12):4690-3. PubMed ID: 18796627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
    Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
    J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.
    Xu H; Valerio DG; Eisold ME; Sinha A; Koche RP; Hu W; Chen CW; Chu SH; Brien GL; Park CY; Hsieh JJ; Ernst P; Armstrong SA
    Cancer Cell; 2016 Dec; 30(6):863-878. PubMed ID: 27889185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.
    Sarma NJ; Yaseen NR
    J Biol Chem; 2011 Nov; 286(45):38989-9001. PubMed ID: 21937451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA export factor RAE1 contributes to NUP98-HOXA9-mediated leukemogenesis.
    Funasaka T; Nakano H; Wu Y; Hashizume C; Gu L; Nakamura T; Wang W; Zhou P; Moore MA; Sato H; Wong RW
    Cell Cycle; 2011 May; 10(9):1456-67. PubMed ID: 21467841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation.
    Quéré R; Karlsson G; Hertwig F; Rissler M; Lindqvist B; Fioretos T; Vandenberghe P; Slovak ML; Cammenga J; Karlsson S
    Blood; 2011 Jun; 117(22):5918-30. PubMed ID: 21471525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Yamagata K; Shino M; Aikawa Y; Fujita S; Kitabayashi I
    Leukemia; 2021 Oct; 35(10):2840-2853. PubMed ID: 33967269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of MLL amino terminal sequences with menin is required for transformation.
    Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
    Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation.
    Slape C; Hartung H; Lin YW; Bies J; Wolff L; Aplan PD
    Cancer Res; 2007 Jun; 67(11):5148-55. PubMed ID: 17545593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SQSTM1-NUP214 fusion protein interacts with Crm1, activates Hoxa and Meis1 genes, and drives leukemogenesis in mice.
    Lavau CP; Aumann WK; Sze SK; Gupta V; Ripple K; Port SA; Kehlenbach RH; Wechsler DS
    PLoS One; 2020; 15(4):e0232036. PubMed ID: 32343715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia.
    Dou Y; Hess JL
    Int J Hematol; 2008 Jan; 87(1):10-8. PubMed ID: 18224408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynein Light Chain 1 (DYNLT1) Interacts with Normal and Oncogenic Nucleoporins.
    Sarma NJ; Yaseen NR
    PLoS One; 2013; 8(6):e67032. PubMed ID: 23840580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
    Jankovic D; Gorello P; Liu T; Ehret S; La Starza R; Desjobert C; Baty F; Brutsche M; Jayaraman PS; Santoro A; Mecucci C; Schwaller J
    Blood; 2008 Jun; 111(12):5672-82. PubMed ID: 18388181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
    Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
    Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model.
    Iwasaki M; Kuwata T; Yamazaki Y; Jenkins NA; Copeland NG; Osato M; Ito Y; Kroon E; Sauvageau G; Nakamura T
    Blood; 2005 Jan; 105(2):784-93. PubMed ID: 15454493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
    Chen L; Sun Y; Wang J; Jiang H; Muntean AG
    Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.
    Gough SM; Slape CI; Aplan PD
    Blood; 2011 Dec; 118(24):6247-57. PubMed ID: 21948299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGFbeta/BMP inhibits the bone marrow transformation capability of Hoxa9 by repressing its DNA-binding ability.
    Wang N; Kim HG; Cotta CV; Wan M; Tang Y; Klug CA; Cao X
    EMBO J; 2006 Apr; 25(7):1469-80. PubMed ID: 16525506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.